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Abstract: Diabetes mellitus is known to exacerbate cerebral ischemic injury. In the present 
study, we investigated antiapoptotic and anti-inflammatory effects of oral supplementation 
of ascorbic acid (AA) on cerebral injury caused by middle cerebral artery occlusion and 
reperfusion (MCAO/Re) in rats with streptozotocin-induced diabetes. We also evaluated 
the effects of AA on expression of sodium-dependent vitamin C transporter 2 (SVCT2) and 
glucose transporter 1 (GLUT1) after MCAO/Re in the brain. The diabetic state markedly 
aggravated MCAO/Re-induced cerebral damage, as assessed by infarct volume and edema. 
Pretreatment with AA (100 mg/kg, p.o.) for two weeks significantly suppressed the 
exacerbation of damage in the brain of diabetic rats. AA also suppressed the production of 
superoxide radical, activation of caspase-3, and expression of proinflammatory cytokines 
(tumor necrosis factor-α and interleukin-1β) in the ischemic penumbra. Immunohistochemical 
staining revealed that expression of SVCT2 was upregulated primarily in neurons and 
capillary endothelial cells after MCAO/Re in the nondiabetic cortex, accompanied by an 
increase in total AA (AA + dehydroascorbic acid) in the tissue, and that these responses 
were suppressed in the diabetic rats. AA supplementation to the diabetic rats restored these 
responses to the levels of the nondiabetic rats. Furthermore, AA markedly upregulated the 
basal expression of GLUT1 in endothelial cells of nondiabetic and diabetic cortex, which 
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did not affect total AA levels in the cortex. These results suggest that daily intake of AA 
attenuates the exacerbation of cerebral ischemic injury in a diabetic state, which may be 
attributed to anti-apoptotic and anti-inflammatory effects via the improvement of 
augmented oxidative stress in the brain. AA supplementation may protect endothelial 
function against the exacerbated ischemic oxidative injury in the diabetic state and improve 
AA transport through SVCT2 in the cortex. 
Keywords: ascorbic acid; diabetes mellitus; oxidative stress; apoptosis; proinflammatory; 
cytokine; sodium-dependent vitamin C transporter 2 (SVCT2); glucose transporter 1 
(GLUT1); rat; streptozotocin; middle cerebral artery occlusion and reperfusion 
 
1. Introduction 
Diabetes mellitus is a metabolic disorder associated with chronic hyperglycemia, which is known to 
enhance systemic oxidative stress, predisposing to diabetic complications. Diabetes is a major risk 
factor for atherosclerotic diseases such as acute brain ischemia [1,2]. Moreover, it increases the risks of 
morbidity and mortality after stroke [3,4]. Oxidative stress plays an essential role in the pathogenesis 
of transient cerebral ischemic injury [3–5]. In particular, reperfusion after a long period of vessel 
occlusion triggers the explosive generation of reactive oxygen species (ROS), such as superoxide 
radical (O2–), hydroxyl radical, hydrogen peroxide, etc., which causes apoptosis and delayed death of 
cells through oxidative damage to lipids, proteins, and DNA in the ischemic penumbral region [6–9]. 
In addition to apoptotic cell death, inflammatory neurodegeneration is another crucial process contributing 
to cerebral damage after ischemia and reperfusion [10]. ROS have been shown to activate nuclear 
factor-κB, which enhances the transcription of the genes encoding proinflammatory cytokines such as 
tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), leading to inflammatory responses [11]. 
Myeloperoxidase (MPO) expressed by microglia, a histopathological marker of inflammation, 
generates cytotoxic ROS and leads to further inflammatory damage in the ischemic tissue [12]. 
Accumulating evidence indicates that hyperglycemia in diabetes is associated with a decrease in the 
antioxidant potential and an increase in ROS generation [13–15]. In addition, diabetes has been shown 
to be a proinflammatory state that increases the risk of vascular complications [16,17]. Thus, the 
enhanced oxidative stress and inflammatory responses in the diabetic state may substantially contribute 
to the aggravation of cerebral injury caused by transient ischemia and subsequent reperfusion. 
L-ascorbic acid (AA) is an essential antioxidant for scavenging free radicals in the brain.  
AA participates not only in sustaining the normal function of the central nervous system (CNS) but in 
ameliorating the damage induced by pathological conditions that increase the generation of ROS [18]. 
The CNS maintains relatively high concentrations of AA, indicating a neuroprotective role for AA [19]. 
The transport of AA from the plasma to the CNS is mainly mediated by sodium-dependent vitamin C 
transporter 2 (SVCT2). In addition, glucose transporter 1 (GLUT1) is located in the endothelial cells of 
the blood–brain barrier (BBB) and transports oxidized AA ([dehydroascorbic acid (DHA)) as another 
source of AA to the brain. Upregulation of SVCT2 [20] and GLUT1 [21] expression has been 
demonstrated in rats with cerebral ischemic injury, which suggests that AA is necessary for protection 
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against oxidative neuronal injury. The concentration of AA is considered to reflect oxidative stress in 
animal tissues sensitively [22]. Patients with ischemic stroke or diabetes have lower concentrations of 
AA in the plasma, suggesting that a systemic decrease in AA is a consequence of enhanced 
consumption of AA by elevated oxidative stress [23,24]. In a previous study, we demonstrated that 
chronic supplementation with AA attenuates oxidative stress in both the plasma and the brain and 
alleviates cerebral injury induced by middle cerebral artery occlusion and reperfusion (MCAO/Re) in 
rats with streptozotocin (STZ)-induced diabetes [25]. We showed that the activity of antioxidant 
enzymes (superoxide dismutase, catalase, and glutathione peroxidase) is decreased, and lipid 
peroxidation is accelerated in the brain of diabetic rats; those detrimental oxidative processes are 
inhibited by AA supplementation. These data suggest that the enhanced oxidative stress in the diabetic 
state causes the functional impairment of antioxidant enzymes, and the resulting diminution in 
antioxidative defense can cause further enhancement of the generation of ROS and subsequent 
neuronal apoptosis and inflammatory neurodegeneration in the ischemic brain. Nonetheless, there is a 
shortage of studies so far on the antiapoptotic and anti-inflammatory effects of AA in cerebral 
ischemia with diabetes. 
In the present study, we evaluated the effects of chronic oral pretreatment with AA on the 
production of O2– and on apoptosis in the brain after MCAO/Re in rats with STZ-induced diabetes. To 
test whether AA suppresses inflammatory responses induced by MCAO/Re, we also examined the 
effects of AA on the expression of TNF-α, IL-1β, and MPO in the brain. Although the transport of AA 
to the CNS is an important factor for its neuroprotection, changes in expression of SVCT2 and GLUT1 
proteins in response to AA supplementation and/or cerebral ischemia in diabetic state have not been 
reported. Therefore, we investigated the effects of AA supplementation on the expression of SVCT2 
and GLUT1 after MCAO/Re in the brain of diabetic rats. 
2. Experimental Section 
2.1. Experimental Animals 
Animal care and surgical procedures were performed in accordance with guidelines approved by the 
National Institutes of Health (Bethesda, MD, USA) and the Josai University Animal Research 
Committee. Male Sprague-Dawley rats (4 weeks old, weight 120–140 g) were purchased from Japan 
SLC (Shizuoka, Japan) and were housed under standard conditions with a temperature-controlled 
environment (23 °C ± 0.5 °C) and a 12 h light/dark cycle. The animals were allowed free access to 
rodent chow (CE-2, CLEA Japan, Tokyo, Japan) and water. Type 1 diabetes was induced in the rats 
(diabetic group) by a single intraperitoneal injection of STZ (50 mg/kg of body weight) dissolved in 
0.1 mM sodium citrate, pH 4.5, while the normal control rats (nondiabetic group) were injected with 
the buffer only [26]. Seven days after the injection of STZ, a blood sample was collected by tail vein 
paracentesis, following which plasma glucose was measured using a glucose analyzer (Ascensia, Bayer 
Yakuhin, Osaka, Japan). Diabetes was defined as a blood glucose level greater than 300 mg/dL. Then, 
the diabetic and nondiabetic groups were divided into 2 groups and were housed for an additional  
6 weeks until stroke was induced by MCAO/Re. AA (L-Ascorbic acid, Wako Pure Chemicals 
Industries, Osaka, Japan) (100 mg/kg; nondiabetic and diabetic AA-supplemented groups) or distilled 
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water (nondiabetic and diabetic control groups) was orally administered through nasogastric tube once 
daily for the last 2 weeks. AA was stored at +4 °C, and dissolved in distilled water fresh each time just 
before administration. 
2.2. MCAO/Re 
The experimental MCAO/Re rat model was prepared as described previously [25]. The rats were 
anesthetized with halothane (4% for induction and 1.5% for maintenance) under spontaneous respiration. 
After a midline incision on the neck, the right common carotid artery was isolated under an operating 
microscope. All branches of the external carotid artery were ligated. The tip of a 4–0 surgical nylon 
monofilament rounded by flame heating was inserted through the internal carotid artery and advanced 
to occlude the origin of MCA. The rectal temperature was maintained at 37 °C with a heat lamp and a 
heating pad during the operation. After 2 h of occlusion, the filament was withdrawn to enable 
reperfusion. The distance from bifurcation of the common carotid artery to the tip of the suture was 
approximately 20 mm in all rats. Cerebral blood flow was detected using a Laser Doppler flowmetry 
(ATBF-LC1, Unique Medical, Tokyo, Japan), and approximately 50% reduction of its baseline 
associated with MCAO was ascertained in the rats. Then, the rats were allowed to recover from 
anesthesia at room temperature and were killed after 24 h of reperfusion. Sham operation involved the 
same manipulations but insertion of the filament. 
2.3. Infarct and Edema Assessment 
After 24 h of reperfusion, the rats were subjected to general halothane anesthesia and decapitated. 
The brain was immediately removed and placed in ice-cold saline. Each brain was then cut into 2 mm 
coronal slices in a rat brain matrix. The brain slices were immediately immersed in 2% 2,3,5-triphenyl 
tetrazolium chloride (TTC, Wako Pure Chemicals Industries, Osaka, Japan) at 37 °C for 15 min and 
then in 4% formaldehyde [26,27]. Infarct areas were identified using an image analysis system (Scion 
Image 1.62, Frederick, MD, USA) and were combined to obtain the infarct volumes per brain according 
to the following formula: corrected infarct volume (%) = (left hemisphere volume − (right hemisphere 
volume − the infarct volume)) × 100/left hemisphere volume. Edema in the ischemic hemisphere was 
also calculated as follows: edema (%) = (right hemisphere volume − the infarct volume)/left 
hemisphere volume × 100. 
2.4. Neurological Evaluation 
Postischemic neurological deficits were evaluated after 24 h of reperfusion on a 5-point scale as 
follows: grade 0, no deficit; grade 1, failure to fully extend the right forepaw; grade 2, spontaneous 
circling or walking to a contralateral side; grade 3, walking only when stimulated; grade 4, unresponsive 
to stimulation and a depressed level of consciousness; and grade 5, death [25,27]. Before MCAO, the 
neurological score was zero in all the rats. The rats that did not exhibit neurological deficits after 
MCAO/Re were excluded from the study. Grades of the neurological score were evaluated by an 
investigator blinded to the treatment protocol. 
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2.5. Detection of O2− Production in the Brain 
Detection of intracellular O2− production in the ischemic penumbral region of the cortex after 
MCAO/Re was performed by histochemical staining of freshly frozen brain sections (8 μm thick) with 
the fluorescent probe dihydroethidium (DHE). The brain sections were immediately incubated with 
DHE (10 μmol/L, Sigma-Aldrich Japan, Tokyo, Japan) in phosphate-buffered saline for 30 min  
at 37 °C [28,29]. To determine the fluorescence intensity of oxidized DHE, 3 visual fields within the 
penumbral cortex regions of each hemisphere were photographed using a confocal laser scanning 
microscope (Fluoview FV1000, OLYMPUS, Tokyo, Japan) with excitation at 510 nm and emission  
at 580 nm. Fluorescence intensity of oxidized DHE was quantified using imaging software  
(FV10-ASW 1.7, OLYMPUS, Tokyo, Japan). Analyses of immunohistochemistry were performed by 
an investigator blinded to the treatment protocol. 
2.6. Immunohistochemistry 
Immunohistochemical staining was performed as described previously [20,30,31]. The brain was 
fixed with 4% phosphate-buffered paraformaldehyde. Coronal brain sections (8 μm thick) were 
incubated with 3% hydrogen peroxide for 40 min at room temperature to inhibit endogenous 
peroxidase and then incubated with blocking buffer (4% Block Ace, Dainippon Sumitomo Pharma, 
Osaka, Japan) for 2 h. Then, the slices were incubated with polyclonal rabbit anti-IL-1β antibody 
(1:300, Santa Cruz Biotechnology, Dallas, TX, USA), polyclonal rabbit anti-TNF-α antibody (1:200, 
Rabbit mAb, Hycult Biotech, Uden, The Netherlands), polyclonal rabbit anti-cleaved caspase-3 
antibody (1:100, Cell Signaling Technology, Danvers, MA, USA), or monoclonal mouse anti-MPO 
(1:100, Hycult Biotech, Uden, The Netherlands), polyclonal rabbit anti-SVCT2 antibody (1:100, Santa 
Cruz Biotechnology, Dallas, TX, USA), polyclonal rabbit anti-GLUT1 antibody (1:100, Santa Cruz 
Biotechnology, Dallas, TX, USA) in 0.01 mol/L phosphate-buffered saline overnight at 4 °C. In a  
double-immunohistchemical study for determination of the cell types of expressing SVCT2 or GLUT1, 
monoclonal mouse anti-neuronal nuclei (NeuN) antibody (1:300, Millipore, Billerica, MA, USA) and 
monoclonal mouse anti-rat endothelial cell antigen (RECA1) antibody (1:200, Abcom, Cambridge, 
UK) were used. After washing with phosphate-buffered saline, the slices were incubated with either 
Cy3- or FITC-conjugated secondary antibody (1:200, Millipore, Billerica, MA, USA) for 2 h at room 
temperature. Finally, the sections were incubated with the nuclear stain TO-PRO-3 (1:10,000, 
Invitrogen, Carlsbad, CA, USA) in phosphate-buffered saline for 10 min at room temperature with 
gentle agitation. Immunofluorescence was visualized using the laser scanning confocal microscope and 
the intensity was measured using the imaging software. Three sections per rat and 3–4 rats per group 
were used for the analyses. 
2.7. Real-Time Polymerase Chain Reaction (PCR) Analysis 
The expression levels of SVCT2 (Slc23a2) and GLUT1 (Slc2a1) mRNA were assessed by quantitative 
real-time polymerase chain reaction (PCR) as described previously [32]. The rats subjected to MCAO 
were killed after 24 h of reperfusion, and total RNA samples were prepared from the ischemic 
penumbral cortex of each rat. Total RNA was extracted using the RNeasy Mini Kit (QIAGEN, Hilden, 
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Germany) according to the manufacturer’s protocol. Total RNA (500 pg) from each sample was 
reverse-transcribed with oligo-dT and random hexamer primers using reverse transcriptase 
(PrimeScript RT Enzyme Mix I; Takara RNA PCR Kit, Takara Biomedicals, Shiga, Japan). Real-time 
PCR was performed with 10 ng of cDNA and a pair of gene-specific primers (Takara Biomedicals, 
Shiga, Japan) that were added to the SYBR Premix EX Taq (Takara Biomedicals, Shiga, Japan) and 
subjected to PCR amplification on the iCycler iQ Real-Time Detection System (Bio-Rad Laboratories, 
Hercules, CA, USA) (1 cycle at 95 °C for 10 s and 50 cycles at 95 °C for 5 s and 60 °C for 34 s).  
β-Actin expression was used to normalize the cDNA levels. The PCR products were analyzed using a 
melting curve to ascertain specificity of the amplification. The data were expressed as mean ± SD 
relative to the sham-operated nondiabetic group. 
2.8. Measurement of Total AA Level 
Total AA (AA + DHA) levels in the plasma and cortex have been determined by spectrophotometric 
method using Vitamin C Assay kit (ROIK02, Shima Laboratories, Tokyo, Japan) which is based on 
2,4-dinitrophenylhydrazine method [33]. Briefly, plasma was mixed with an equal volume of 10% 
metaphosphoric acid solution. Cortex tissue was mixed with 14 times volume of 5.4% metaphosphoric 
acid solution and homogenized. After centrifugation of the solutions at 10,000× g for 15 min at 4 °C, 
the supernatants were used to the assay. 
2.9. Statistical Analysis 
Two-way ANOVA, followed by post hoc Tukey’s multiple-comparison test, was used for statistical 
analysis. Neurological deficit scores were analyzed using the Kruskal-Wallis test, followed by the 
Mann-Whitney U test. In all cases, a p value of <0.05 was assumed to denote statistical significance. 
3. Results 
3.1. Blood Glucose and Body Weight 
Body weight and blood glucose data from the experimental rats were obtained throughout the study 
period (Table 1). Similar to our previous study [25], the diabetic control group of rats had a significantly 
decreased body weight and an increased blood glucose level compared with the nondiabetic control 
group. There were no significant differences in those parameters between the AA-supplemented 
groups and their controls. 
Table 1. Effects of oral supplementation with AA on body weight and blood glucose levels 
in nondiabetic (non-DM) and diabetic (DM) groups of rats. 
Groups Body Weight (g) Blood Glucose (mg/dL) 
Non-DM 335 ± 16 112 ± 11 
Non-DM + AA 340 ± 23 135 ± 9 
DM 255 ± 32 * 485 ± 42 * 
DM + AA 269 ± 36 * 469 ± 71 * 
The data are shown as mean ± SD. * p < 0.01 vs. the nondiabetic group (n = 6–7). 
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3.2. Ischemic Brain Injury and Neurological Deficits 
Figure 1 shows MCAO/Re-induced brain injury in the nondiabetic control, nondiabetic + AA, 
diabetic control, and diabetic + AA groups of rats. Examples of TTC staining in the coronal brain 
sections at 24 h after MCAO/Re are shown in Figure 1A. The infarct developed in the corpus striatum 
and cortex of the nondiabetic control rats. In the diabetic rats, the infarction zone was remarkably 
enlarged and extended to a large part of the left striatum and cortex. In contrast, the infarcts in the  
AA-supplemented groups were smaller than those in their respective controls. Quantitative assays 
revealed that the infarct volume and edema in the diabetic control group were significantly increased 
by approximately 2.5-fold and 2-fold, respectively, compared with those in the nondiabetic control 
group (Figure 1B,C). AA supplementation in the nondiabetic group significantly decreased infarction 
and edema. Furthermore, AA almost completely suppressed the exacerbation of brain damage by diabetes. 
Figure 1. Effects of AA supplementation on infarction induced by MCAO/Re in the brain 
of nondiabetic and diabetic rats. (A) Representative photographs of staining of coronal 
brain sections from the rats of the nondiabetic + sham operation group and from distilled 
water-administered (Control) or AA (100 mg/kg)-supplemented nondiabetic or diabetic 
groups with MCAO with reperfusion (MCAO/Re). AA or water was orally administered 
once daily for 2 weeks; (B) Infarct volume in ischemic hemispheres of the diabetic and 
nondiabetic groups after MCAO/Re by TTC staining; (C) Edema volume in ischemic 
hemispheres of the diabetic and nondiabetic groups after MCAO/Re. Data are presented as 
means ± SD (n = 6–7). ** p < 0.01 compared with the nondiabetic control group.  
## p < 0.01 compared with the diabetic control group. DM in the figure denotes diabetic, 
while non-DM denotes nondiabetic. 
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Consistent with the aforementioned results of the brain injury experiments, neurological deficits 
were exacerbated in the diabetic control group of rats (Figure 2). Compared with the diabetic control 
group, the diabetic + AA group showed significant alleviation of the neurological deficits. 
Figure 2. Effects of AA supplementation on neurological deficits induced by MCAO/Re in 
nondiabetic and diabetic rats. Postischemic neurological deficits were evaluated on a  
5-point scale at 24 h of reperfusion after 2 h of MCAO. Data are mean ± SD of 6–7 rats per 
group. ** p < 0.01 compared with the nondiabetic control group. ## p < 0.01 compared with the 
diabetic control group. DM in the figure denotes diabetic, while non-DM denotes nondiabetic. 
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3.3. O2– Production after Ischemia with Reperfusion 
Figure 3 shows fluorescence intensity of DHE in the penumbral cortex, which depends on intracellular 
O2– production. Representative histological images of DHE staining in the nondiabetic control, 
nondiabetic + AA, diabetic control, and diabetic + AA groups are shown in Figure 3A. DHE-positive 
cells with low fluorescence intensity were sparsely distributed in the cortex of sham-operated 
nondiabetic rats. In contrast, sham-operated diabetic rats had an increased number of DHE-positive 
cells with higher fluorescence intensity in the cortex, indicating basal augmentation of the generation 
of ROS in the brain of the diabetic rats. The intensity of DHE fluorescence was remarkably increased 
by MCAO/Re in the nondiabetic rats and was further augmented in the diabetic rats, suggesting that 
the exacerbated injury can be attributed to enhanced generation of ROS in diabetes. AA supplementation 
significantly reduced the fluorescence of DHE in the cortex of the nondiabetic and diabetic rats 
compared with that in their respective controls. 
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Figure 3. Effects of AA supplementation on production of O2– after MCAO/Re in the brain 
of nondiabetic and diabetic rats. (A) Representative photographs of superoxide production 
detected by DHE staining in coronal sections of the cortex from the nondiabetic and 
diabetic rats; (B) Quantitative analysis of DHE fluorescence intensity in the cortex. The 
data are presented as mean ± SD (n = 3–4). * p < 0.05, ** p < 0.01 compared with the 
nondiabetic control group. # p < 0.05, ## p < 0.01 compared with the diabetic control group. 
DM in the figure denotes diabetic, while non-DM denotes nondiabetic. 
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3.4. Apoptosis Induced by Ischemia with Reperfusion 
Activation of caspase-3, a key mediator of the execution phase of apoptosis, was determined by 
immunostaining for cleaved caspase-3, which is an activated form of this enzyme, in the ischemic 
penumbral cortex of the four experimental groups after MCAO/Re (Figure 4). Compared with the 
nondiabetic control group, the number of cleaved caspase-3 positive cells was remarkably increased by 
MCAO/Re in the diabetic control group. AA significantly attenuated the MCAO/Re-induced activation 
of caspase-3 in the nondiabetic and diabetic groups. 
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Figure 4. Effects of AA supplementation on cleaved caspase-3 after MCAO/Re in the 
brain of nondiabetic and diabetic rats. (A) Representative photographs of cleaved caspase-3 
immunostaining in the cortex coronal sections of nondiabetic and diabetic rats;  
(B) Quantitative analysis of cleaved caspase-3 positive cells (fluorescence intensity in the 
cortex). The data are presented as mean ± SD (n = 3–4). * p < 0.05, ** p < 0.01 compared 
with the nondiabetic control group. ## p < 0.01 compared with the diabetic control group. 
DM in the figure denotes diabetic, while non-DM denotes nondiabetic. 
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3.5. Expression of IL-1β, TNF-α, and MPO in the Cortex 
To assess the effects of AA supplementation on the expression of proinflammatory cytokines, we 
performed immunohistochemical staining for IL-1β and TNF-α. This experiment confirmed upregulation 
of the protein level of these cytokines as a result of MCAO/Re and diabetes (Figures 5 and 6). 
Quantification of the immunostaining data showed that the sham-operated diabetic control group had a 
significant increase in IL-1β and TNF-α expression compared with the sham-operated nondiabetic 
control group, suggesting basal augmentation of the inflammatory response in the diabetic brain. 
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MCAO/Re significantly increased the expression levels of those proinflammatory cytokines in the 
nondiabetic cortex. The ischemia-induced upregulation of those cytokines was markedly accelerated 
by diabetes: the diabetic control group showed a 15.9- and 21.0-fold increase in IL-1β and TNF-α 
expression, respectively, compared with the nondiabetic control group. AA supplementation significantly 
suppressed the basal and ischemia-enhanced expression of these cytokines in diabetic rats. 
Figure 5. Effects of AA supplementation on expression of IL-1β in the penumbral cortex 
after MCAO/Re in the brain of nondiabetic and diabetic rats. (A) Representative photographs 
of IL-1β immunostaining (red fluorescence) and staining of nuclei by TO-PRO-3 (blue 
fluorescence) in the cortex coronal sections of nondiabetic and diabetic rats; (B) Quantitative 
analysis of IL-1β fluorescence intensity in the cortex. The data are presented as mean ± SD 
(n = 3–4). ** p < 0.01 compared with the nondiabetic control group. # p < 0.05 compared 
with the diabetic control group. DM in the figure denotes diabetic, while non-DM  
denotes nondiabetic. 
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Figure 6. Effects of AA supplementation on expression of TNF-α in the penumbral cortex 
after MCAO/Re in the brain of nondiabetic and diabetic rats. (A) Representative photographs 
of TNF-α immunostaining (red fluorescence) and staining of nuclei by TOPRO-3 (blue 
fluorescence) in the cortex coronal sections of nondiabetic and diabetic rats; (B) Quantitative 
analysis of TNF-α fluorescence intensity in the cortex. The data are presented as mean ± SD 
(n = 3–4). ** p < 0.01 compared with the nondiabetic control group. # p < 0.05 compared 
with the diabetic control group. DM in the figure denotes diabetic, while non-DM  
denotes nondiabetic. 
(A)
0
(B)
10
20
30
Sham
non-DM control
non-DM + AA
DM control
DM + AA
MCAO/Re
#3TNF-α MergeTNF-α Merge
Sham
non-DM
DM
TO-PRO-3 TO-PRO-3
Control
AA
Control
AA
MCAO/Re
** #
**
#
Fl
uo
re
sc
en
ce
 o
f T
N
F-
α/T
O
-P
R
O
3 
re
la
tiv
e 
to
 s
ha
m
-o
pe
ra
te
d 
no
n-
D
M
100 μm
Fl
uo
re
sc
en
ce
 o
f T
N
F-
α/T
O
-P
R
O
3 
re
la
tiv
e 
to
 s
ha
m
-o
pe
ra
te
d 
no
n-
D
M
 
In the nondiabetic rat cortex, the protein expression of MPO was markedly upregulated after 
MCAO/Re (Figure 7). AA supplementation abrogated the ischemia-induced increase in MPO 
expression. Compared with the nondiabetic rats, the basal level of MPO expression increased only 
slightly in the diabetic rats. MCAO/Re upregulated the expression of MPO to the level similar to that 
in the nondiabetic group. AA supplementation had no effect on the ischemia-induced increase in the 
MPO level in the diabetic rats. 
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Figure 7. Effects of AA supplementation on MPO expression after MCAO/Re in the brain 
of nondiabetic and diabetic rats. (A) Representative photographs of MPO immunostaining 
in the cortex coronal sections of nondiabetic and diabetic rats; (B) Quantitative analysis of 
MPO fluorescence intensity in the cortex. The data are presented as mean ± SD (n = 3–4). 
* p < 0.05 compared with the nondiabetic control group. DM in the figure denotes diabetic, 
while non-DM denotes nondiabetic. 
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3.6. Expression of SVCT2 and GLUT1 in the Cortex 
The expression and transport activity of SVCT2 as a specific transporter of AA in the CNS have 
been reported to be enhanced after MCAO/Re in mice [20]. In addition, DHA is known to be transported 
across the BBB via GLUT1 [19]; thus, we investigated effects of AA supplementation on changes in 
the expression of SVCT2 and GLUT1 mRNA in diabetic animals with or without MCAO/Re  
(Figure 8). There was no significant difference in the basal expression levels of SVCT2 mRNA 
between the nondiabetic and diabetic groups or between each of them and their AA-supplemented 
Nutrients 2014, 6 1567 
 
 
groups. In the nondiabetic and nondiabetic + AA groups, the expression level of SVCT2 mRNA was 
equally upregulated at 24 h after MCAO/Re. In contrast, the upregulation of ischemia-induced  
SVCT2 mRNA expression was not observed in the diabetic control group, whereas it was observed in 
the diabetic + AA group. Compared with the nondiabetic control group, the diabetic state significantly 
downregulated the expression of GLUT1 mRNA in the cortex. AA supplementation increased the 
expression of GLUT1 in the nondiabetic and diabetic rats. In the nondiabetic and diabetic control 
groups, MCAO/Re had a stimulating effect on the expression of GLUT1 mRNA that was similar to  
the effect of AA supplementation. Further enhancement by ischemia was not detected in the  
AA-supplemented groups. 
Figure 8. Effects of AA supplementation on SVCT2 and GLUT1 mRNA expression in the 
ischemic penumbral cortex of nondiabetic and diabetic rats. Expression levels of SVCT2 
mRNA (Slc23a2) (A) and GLUT1 mRNA (Slc2a1) (B) were assessed using real-time PCR 
analysis of the penumbral cortex of nondiabetic and diabetic rats after MCAO/Re. The data 
are presented as mean ± SD (n = 3–6). † p < 0.05, †† p < 0.01 compared with the respective 
sham-operated controls. * p < 0.05, ** p < 0.01. 
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To assess the effects of AA supplementation on the expression of SVCT2 protein after MCAO/Re 
in detail, the localization and the expression levels of SVCT2 in the penumbral cortex were examined 
by immunohistochemical staining (Figure 9A). Double immunofluorescence staining with antibodies 
of anti-SVCT2 and anti-NeuN, a biomarker for neurons, revealed that majority of the cells exhibiting 
SVCT2 expressed NeuN in the sham-operated nondiabetic and diabetic rat cortex (Figure 9A). In addition, 
the cells exhibiting the endothelial cell maker RECA1 showed a low level of SVCT2-immunoreactivity 
(Figure 9B). These expression levels in the neurons and capillary endothelial cells of SVCT2 were 
upregulated by MCAO/Re in the nondiabetic rats, but not in the diabetic rats. In agreement with the 
results from the mRNA measurement, quantification of the immunofluorescence revealed that the 
expression levels of SVCT2 immunoreactivity were significantly increased in response to MCAO/Re 
both in the nondiabetic control and AA-supplemented nondiabetic groups (Figure 9C). This reaction 
against MCAO/Re was abrogated in the diabetic control group, whereas the AA-supplemented diabetic 
rats showed an increased expression of SVCT2 in the cortex after MCAO/Re. 
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Figure 9. Effects of AA supplementation on SVCT2 and GLUT1 expression in the 
ischemic penumbral cortex of nondiabetic and diabetic rats. Expression levels of SVCT2 
(A–C) and GLUT1 (D,E) were assessed using immunohistostaining of the penumbral 
cortex of nondiabetic and diabetic rats after MCAO/Re. Immunohistochemical expression 
of SVCT2 (red fluorescence) merged with NeuN (A) or with RECA1 (B) (green fluorescence); 
(C) Quantitative analysis of SVCT2 fluorescence intensity in the cortex. # p < 0.05,  
## p <  0.01. * p < 0.05, ** p < 0.01 compared with the respective sham-operated 
nondiabetic controls; (D) Immunohistochemical expression of GLUT1 (red fluorescence) 
merged with RECA1 (green fluorescence); (E) Quantitative analysis of SVCT2 
fluorescence intensity in the cortex. * p < 0.05, ** p < 0.01 compared with the respective 
sham-operated nondiabetic controls. † p < 0.05, †† p < 0.01 compared with the respective 
sham-operated diabetic controls. 
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Figure 9. Cont. 
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On the other hand, GLUT1 immunoreactivity was predominantly colocalized with RECA1  
(Figure 9D). Some of the cells exhibiting NeuN showed a weak GLUT1-immunoreactivity (data not 
shown). In the sham-operated nondiabetic and diabetic groups with AA supplementation, the expression 
levels of GLUT1 in the capillary endothelial cells were remarkably upregulated. Additionally, 
MCAO/Re showed a stimulating effect on the GLUT1 expression both in the nondiabetic and diabetic 
cortex. Quantitative analyses of immunofluorescence in the sections revealed that the sham-operated 
diabetic control rat cortex had a lower expression level of GLUT1 compared with the nondiabetic rat 
cortex, and AA supplementation or MCAO/Re caused a significant increase in the expression of 
GLUT1 (Figure 9E). 
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3.7. Total AA Levels in the Plasma and Cortex 
To determine whether the changes in expression levels of SVCT2 and GLUT1 induced by AA 
supplementation or by MCAO/Re affect the concentrations of AA in the cortex, we measured total AA 
(AA + DHA) levels in the plasma and cortex of the experimental groups (Figure 10). It has been 
indicated that reduction of DHA to AA or decomposition of DHA to 2,3-diketo-1-gulonic acid is rapid 
in the plasma and brain, and that the concentrations of DHA in these tissues are 0%–2% of AA [19]. 
Therefore, total AA levels are considered to almost equal to the AA levels. The plasma of the  
sham-operated diabetic control rats had a significant smaller amount of total AA levels compared with 
the nondiabetic rats (Figure 10A). AA supplementation restored the decrement of the total AA levels 
in the diabetic rats to almost the same levels as those in the nondiabetic control rats. MCAO/Re had 
little effect on the total AA levels in the plasma of all groups. In contrast, neither diabetic state nor AA 
supplementation affected the total AA levels in the cortex of sham-operated groups. MCAO/Re 
significantly decreased the total AA levels both in the nondiabetic and diabetic cortex. AA 
supplementation to the diabetic rats caused a significant increase in the total AA levels in the cortex in 
response to MCAO/Re. 
Figure 10. Effects of AA supplementation on levels of total AA (AA + DHA) in the 
plasma and cortex of nondiabetic and diabetic rats. Total AA (AA + DHA) levels in the 
plasma (A) and cortex (B) measured in nondiabetic and diabetic rats after MCAO/Re. The 
data are presented as mean ± SD (n = 3–6). * p < 0.05, ** p < 0.01. 
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4. Discussion 
The present study confirmed that the STZ-evoked diabetic state aggravates neuronal damage caused 
by a transient cerebral ischemia and subsequent reperfusion in rats. We found that diabetes enhances 
the production of O2−, activates caspase-3, and induces the expression of proinflammatory cytokines 
(TNF-α and IL-1β) in the brain. These detrimental effects are markedly potentiated by cerebral 
ischemia and reperfusion, leading to greater infarct growth and aggravation of apoptosis and 
inflammation. Our results show that chronic supplementation with AA inhibits the apoptotic changes 
and proinflammatory responses, and attenuates the exacerbation of cerebral injury and neurological 
deficits in the diabetic state. These beneficial effects of AA could be attributed to its antioxidant and 
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anti-inflammatory properties. We observed that the expression level of SVCT2 increases in response to 
MCAO/Re in the nondiabetic cortex, which is accompanied by an increase in the total AA (AA + DHA) 
in the tissues, and that these responses are abolished in the diabetic rats. AA supplementation to the 
diabetic rats restored these responses to the levels of the nondiabetic rats. Therefore, supplementation 
with AA may enhance the transport of AA into neuronal cells, resulting in reinforcement of the 
antioxidant defense and alleviation of oxidative ischemic injury in the brain of diabetic rats. 
Because rats can synthesize their own AA, unlike humans, they seem to hardly suffer from low 
levels of internal AA [19]. However, there is experimental evidence that STZ-induced type 1 diabetic 
rats have low levels of AA in the plasma, liver, kidney, and other tissues [23,34,35]. It is conceivable 
that the enhanced oxidative stress in diabetes consumes the circulating AA and that the resulting 
diminution in the AA concentration leads to further enhancement of the reactions mediated by free 
radicals. This study indicates that the diabetic rats have low levels of AA in the plasma, and that 
chronic oral pretreatment with AA in diabetic rats decreases the cerebral O2− generation, apoptosis, 
and infarction induced by MCAO/Re; all of these effects could be a result of improved antioxidant 
status in the diabetic brain. Indeed, we observed that AA supplementation to the diabetic rats prevents 
the diminution of the total AA levels in the cortex associated with ischemia-reperfusion. On the other 
hand, we found that AA supplementation causes insufficient downregulation of proinflammatory 
cytokines and has no effect on MPO expression in diabetic rats after MCAO/Re. The relative low dose 
of AA (100 mg/kg) which we used in this study might not be efficacious against the severe 
inflammatory responses induced by the combination of stroke and diabetes. 
Concentrations of AA in plasma and peripheral extracellular fluid after ingestion are strictly 
controlled by intestinal absorption, tissue transport, and renal excretion. Chen et al. [36] shows that 
orally administrated AA at doses >200 mg/kg is declined to ≈60 μM in plasma and extracellular fluid 
of femoral muscle in rats. In the brain, concentration of AA is relatively high compared with that in the 
plasma [24]. Two mechanisms of AA recruitment into the brain are known: the transport of AA 
through SVCT2, a specific transporter for AA, and the transport of DHA across the BBB through 
GLUT1 with subsequent immediate reduction in the brain. The gradation of AA concentrations 
between the plasma and the CNS is thought to be maintained by SVCT2, because AA is mainly 
present in the reduced form in the plasma. On the other hand, the cerebroprotective effects of AA 
supplementation remain controversial, whereas beneficial effects of DHA administration for neuronal 
oxidative stress and inflammation seem to be well established [37–39]. Previous studies do not support 
acute cerebroprotective effects of treatment with AA under normal conditions because AA is not 
transported into the brain rapidly, owing to the high affinity and low ability for AA transport by 
SVCT2. Ahn and colleagues [40] reported that chronic AA supplementation has little or no effect on 
elevated oxidative stress in STZ-induced diabetic brain, whereas it is efficacious in the liver and 
kidneys. This phenomenon can be attributed to a lack of SVCT2 expression in endothelial cells of the 
BBB [41,42]. Recently, the evidence indicating that AA supplementation suppresses diabetes or 
ischemia-induced oxidative damage in the hippocampus and cortex of experimental animals has been 
accumulated [43–45]. These regions are not only vulnerable to oxidative stress but abundant in SVCT2 
compared to other regions in the brain, namely, there may be some kinds of differences in sensitivity 
for AA supplementation depending on brain regions. Therefore, it seems possible that previous 
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experiments using whole-brain samples might have not been adequate to detect the cerebroprotective 
effects of AA supplementation. 
The system of DHA transport through GLUT1 in the BBB may not substantially contribute to total 
brain AA concentrations under normal conditions, because DHA concentrations in the plasma are 
usually only 0%–2% of AA concentrations [19,46]. Nonetheless, during oxidative stress in the CNS 
such as stroke and/or treatment with DHA, this route could play a significant role in the recruitment of 
AA [39,47]. Our study demonstrated that diabetes downregulates the expression of GLUT1 in the 
cortex, in line with previous studies [21,25]. AA supplementation to the diabetic rats markedly 
upregulated the basal expression of GLUT1; however, it exerted no significant increase in the total AA 
levels in the cortex of the rats. Taken together, contribution of the DHA transport system through 
GLUT1 to the cerebroprotection seems to be limited in the diabetic rats. The upregulation of GLUT1 
expression by AA supplementation was observed also in the cortex of nondiabetic sham-operated 
group, despite that there were little changes in the total AA levels in the plasma of the rats. These 
results may indicate that orally supplemented AA has no direct enhancing effect on the expression of 
GLUT1 in the nondiabetic rats. However, AA concentration in the plasma is considered to increase 
within several hours after oral administration and decline to the basal level 24 h after the administration 
by excretion of the excess of AA, at which we collected the plasma samples from the experimental 
animals. Therefore, one possibility is that intermittent increases in AA concentration in the plasma 
repeated for two weeks could stimulate expression of GLUT1 in the cortex. Future research needs to 
be done with regard to the detailed mechanism underlying the upregulation of GLUT1 expression by 
AA supplementation. 
SVCT2 has been shown to be crucial for maintaining AA for protection against oxidative stress in 
the CNS. It has been shown that cultured cells lacking this protein are vulnerable to oxidative  
stress [18]. In the present study, diabetes itself caused no apparent changes in the expression of SVCT2 
in the cortex. On the other hand, after MCAO/Re, the expression of SVCT2 in the penumbral cortex, 
of which the majority seems to be localized in neurons, is upregulated in the nondiabetic rats. Gess and 
colleagues [20] have demonstrated that SVCT2 is specifically expressed in brain capillary endothelial 
cells and transports AA across the BBB during the subacute phase after MCAO/Re in mice. We also 
observed that expression levels of SVCT2 in capillary endothelial cells are increased after MCAO/Re 
in the nondiabetic rat cortex. This has been proposed as one of the mechanisms that protect the brain 
against oxidative injury under pathological conditions such as stroke and neurodegeneration. In contrast, 
we found that the upregulation of SVCT2 expression was abrogated in the diabetic rats, suggesting that 
the cerebroprotective mechanism via AA recruitment may be disrupted in the diabetic state. The 
abnormality of endothelial cell function in STZ-diabetic rats has been indicated to be related to the 
ROS generation in microvascular walls [17]. Seno and coworkers [48] demonstrated that the inflammatory 
cytokines TNF-α and IL-1β suppress the transport of AA through SVCT2 in human umbilical vein 
endothelial cells. Indeed, we detected a robust increase in the expression these cytokines in the brain of 
diabetic rats after MCAO/Re, which may reverse the upregulation of SVCT2 by MCAO/Re itself. AA 
supplementation to the diabetic rats upregulated the expression of SVCT2 in the cortex and restored 
the total AA levels to the nondiabetic levels. The antioxidative properties of AA may protect 
endothelial functions including the transcriptional regulation of SVCT2 against the exacerbated 
ischemic oxidative injury and the enhanced proinflammatory responses in the diabetic state, and may 
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improve AA transport through SVCT2 in the BBB. Further experiments using radiolabeled tracers or 
other rodent models such as SVCT2+/− mice are needed to elucidate these cerebroprotective 
mechanisms of AA, including its effects on the specific transport of AA into the diabetic brain. 
5. Conclusions 
In the present study, we found that chronic AA supplementation inhibits the apoptotic and 
proinflammatory changes and attenuates the exacerbation of cerebral injury and neurological deficits 
in the diabetic state. These phenomena could be attributed to the antioxidant activity and  
anti-inflammatory effects of AA. Diabetes repressed the enhancement of SVCT2 expression induced 
by ischemia-reperfusion in the neurons and capillary endothelial cells, whereas the downregulated 
expression of SVCT2 was restored to control levels by AA supplementation. Therefore, chronic AA 
supplementation may enhance and normalize the transport of AA into the CNS and may thus reinforce 
the antioxidant defense and alleviate oxidative ischemic injury in the brain of diabetic rats. 
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